Tiago Outeiro on For α-Synuclein Immunotherapy, Is Going Later the Key?
COMMENT While the outcome of the trial is disappointing, the study was very important, as it tested an important hypothesis in the field—whether targeting α-synuclein using immunotherapy would be beneficial in PD. This is important because α-synuclein pathology ...